Section Edited by Ignacio Melero, MD, PhD and Alexandra Snyder Charen, MD
This section focuses on the discovery, development and/or clinical significance of biomarkers for immunomodulatory anti-cancer treatments. This includes biomarkers for diagnostic, prognostic, predictive and pharmacodynamic purposes measured using diverse strategies including, but not limited to, genomic or gene expression,serological analyses, cell-based or single-cell studies, in situ/localized tissue-based protein imaging, high content/multiparametric molecular platforms and imaging studies conducted in model systems, retrospective collections and clinical trials.This section also welcomes studies reporting novel methods, technologies or computational approaches to interrogate the anti-tumor immune response that have the potential to advance the field. Manuscripts will be prioritized for peer review and publication on the basis of innovation/novelty of the biomarker-oriented research, adequate validation, clinical relevance and technological novelty. Special emphasis is assigned to: 1) Rigorous analytical validation of assays used (e.g. antibodies, mRNA probes, DNA sequences, molecular biosensors and modified reagents); 2) Reproducibility of findings in multiple populations/datasets/models; and 3) Use of appropriate statistics to account for cases stratification (e.g. cut-point selection), data overfitting and multiple hypothesis testing (e.g. adjustment of significance thresholds, P-values or other strategies to reduce type I error).
